1993), and heterozygous animals for both knockouts did not exhibit an obvious clinical phenotype (Araki et al., 1994; Tamemoto et al., 1994; Accili et al., 1996; Joshi et al., 1996) . Therefore, to create a polygenic mouse model for NIDDM that might more closely mimic the human disease, we have generated mice with combined heterozygous deficiencies in the IR and IRS-1 genes. These animals are lean but highly insulin resistant, and 40% develop NIDDM between the ages of 4 and 6 months, despite massive hyperinsulinemia and pancreatic ␤ cell hyperplasia. These animals provide a new understanding of the genetic and molecular mechanisms underlying NIDDM in which the combination of two mild defects in the insulin signaling cascade give rise to insulin resistance and subsequent progression to a diabetic phenotype.
Results

IR/IRS-1 (ϩ/Ϫ) Mice Develop Normally, While IR/IRS-1 (Ϫ/Ϫ) Mice Die from Diabetic Ketoacidosis
Mice double heterozygous for IR and IRS-1 null alleles were obtained by breeding mice heterozygous for either mutation alone and identified according to the scheme outlined in Figure 1A . These IR/IRS-1 (ϩ/Ϫ) mice were born with the expected Mendelian frequency of 25% and were indistinguishable from wild-type, IRS-1 (ϩ/Ϫ), and IR (ϩ/Ϫ) mice. Their extrauterine development proceeded at normal rates, with a slight, nonsignificant decrease in body weight ( Figure 1B ). Simultaneously, mice homozygous for null mutations in both genes were created by mating male and female IR/IRS-1 double heterozygote mice or IRS-1 (Ϫ/Ϫ) IR (ϩ/Ϫ) male mice with double heterozygote IR/IRS-1 females. Mice homozygous for the IR null allele, either alone or in combination with the null allele in the IRS-1 locus, were also born with the expected frequency. As previously described for the IR (Ϫ/Ϫ) mice, animals of these genotypes died within 72 hr of birth due to uncontrolled diabetes. Blood glucose concentrations, determined 24 hr after birth, the mean ϩ/Ϫ SEM for at least four animals of each genotype.
anti-IRS-1, anti-IRS-2, and anti-p85 antibodies, followed by Western blot analysis with the respective antibodies. If a null allele for IR was present either alone or in combination with an IRS-1 null allele, expression of IR was reduced in approximate proportion to gene dosage. Quantification of multiple experiments showed an ‫%06ف‬ reduction in IR expression in liver ( Figure 2A ) and muscle (data not shown) of heterozygote IR (ϩ/Ϫ) animals. Similarly, inactivation of one allele of the IRS-1 gene resulted in an ‫%06ف‬ reduction in IRS-1 protein expression (Figure 2B ). As expected, the expression of the alternative substrate of the insulin receptor kinase, IRS-2, and of the p85 regulatory subunit of PI 3-kinase was unaltered by the presence of either the IR or IRS-1 null alleles ( Figure 2C ). Short-term administration of insulin had no effect on the expression of the insulin signaling molecules examined.
To determine the consequence of reduced insulin receptor and IRS-1 expression on insulin-stimulated signaling, we investigated the early signaling events in both liver and muscle. In wild-type animals, insulin rapidly stimulated the tyrosine autophosphorylation of the insulin receptor, and this was unaltered in IRS-1 (ϩ/Ϫ) mice ( Figure 3A ). In IR (ϩ/Ϫ) and IR/IRS-1 (ϩ/Ϫ) mice, the 60% reduction of insulin receptor expression led to a similar reduction in receptor autophosphorylation (Figure 3A) . As with insulin receptor phosphorylation, wildtype animals also exhibited a robust stimulation of IRS-1 phosphorylation ( Figure 3B ). Reduction of IRS-1 expression alone in IRS-1 (ϩ/Ϫ) mice or reduction of insulin receptor alone in IR (ϩ/Ϫ) mice led to a 40%-50% reduced tyrosine phosphorylation of IRS-1 ( Figure 3B ). In double heterozygous animals, combined deficiency of one copy of the IR and one copy of the IRS-1 gene led to a 70% reduction of insulin-stimulated tyrosine phosphorylation of IRS-1 ( Figure 3B ). Thus, the combined deficiency for the insulin receptor and IRS-1 resulted in an additive effect on impairment of this step in insulin signaling.
IRS-2 is an alternative substrate of the insulin receptor kinase and provides a partial compensation for insulin and IGF-1 (insulin-like growth factor-1) signaling in homozygous IRS-1-deficient mice (Araki et al., 1994; Patti et al., 1995) . In livers of wild-type mice, IRS-2, like IRS-1, becomes rapidly tyrosine phosphorylated following insulin administration ( Figure 3C ). Reduced expression of IRS-1 in the IRS-1 (ϩ/Ϫ) mice led to an ‫%02ف‬ increase in IRS-2 phosphorylation ( Figure 3C ). Since this occurs without an increase in IRS-2 expression, this suggests IRS-1 (ϩ/Ϫ) mice ( Figure 3C ). Thus, the double heterozyor insulin (ϩ) in the inferior vena cava after an overnight starvation gote mice exhibited a 40% impairment of both insulin period were subjected to immunoprecipitation with an anti-insulin receptor and IRS-2 phosphorylation due to reduced in- (upper panel) and p85, the regulatory subunit of PI 3-kinase (lower (B) The experiment was performed as described in (A), with the panel), in liver of the different mutant mice. Immunoprecipitation exception that immunoprecipitation and Western blotting were perand Western blotting were performed as described in Experimental formed with an antibody against IRS-1.
Procedures. phosphorylation due to combined deficiency in both genes. IRS-1 and IRS-2 mediate further downstream signaling events by binding to SH2 domain-containing proteins via their tyrosine-phosphorylated motifs. One of the SH2 proteins implicated in mediating insulin-stimulated glucose transport and other metabolic signals is the p85 regulatory subunit of PI 3-kinase that binds to phosphorylated IRS-1, resulting in activation of the p110 catalytical subunit. Association of p85 with IRS-1 was reduced by 40% in liver of IRS-1 (ϩ/Ϫ) mice and IR (ϩ/Ϫ) mice and by 60% in IR/IRS-1 (ϩ/Ϫ) mice, paralleling the decreased IRS-1 phosphorylation in these mice ( Figure  3D ). In contrast, IRS-2-associated p85 was unaltered in the IRS-1 (ϩ/Ϫ) mice, despite the modest increase in insulin-stimulated IRS-2 phosphorylation ( Figure 3E ). Reduction of insulin receptor expression, on the other hand, resulted in a 40% reduction in insulin-stimulated unit was reduced by 50% in the muscle of IR (ϩ/Ϫ) and IR/IRS-1 (ϩ/Ϫ) mice ( Figure 4 , upper panel). Insulinstimulated tyrosine phosphorylation of IRS-1 and assoantibody. As previously described, in the wild-type mice the only signal detectable in this assay was a broad ciation of p85 to IRS-1 was reduced by ‫%05ف‬ in IRS-1 (ϩ/Ϫ) and IR (ϩ/Ϫ) mice and by ‫%08ف‬ in IR/IRS-1 (ϩ/Ϫ) band in the molecular weight range of ‫581ف‬ kDa, which represents both tyrosine-phosphorylated IRS-1 and mice ( Figure 4 , middle panels).
Examination of IRS-2 expression and its tyrosine IRS-2 ( Figure 4 , lower panel). In IR (ϩ/Ϫ) or IRS-1 (ϩ/Ϫ) mice, this signal was reduced by ‫,%05ف‬ paralleling the phosphorylation upon insulin stimulation, however, revealed an important difference in insulin signaling bedecrease in IRS-1 phosphorylation in these animals. In the double heterozygote, the pp185 band was almost tween liver and muscle. While there was a significant amount of IRS-2 detectable in liver extracts from mice undetectable, indicating that IRS-1 is the major insulin signaling component in muscle mediating insulin stimuof the different genotypes, immunoprecipitation from muscle extracts using IRS-2-specific antisera revealed lation of PI 3-kinase and that very little tyrosine-phosphorylated IRS-2 is available to bind p85. a very weak signal, suggesting that IRS-2 expression in muscle is low as compared to its expression in liver.
To address the question as to what extent insulin Consequence of Impaired Insulin Signaling in IR/IRS-1 (ϩ/Ϫ) Mice stimulated association of p85 to any cellular tyrosine phosphoprotein in muscle, we prepared anti-p85 immuon Glucose Homeostasis Despite the reductions in insulin receptor and IRS-1 noprecipitates from muscle extracts and subjected them to Western blotting with an anti-phosphotyrosine protein, there was no detectable difference in blood for untreated animals; closed bars, values for insulin-treated animals.
(B) Insulin-stimulated tyrosine phosphorylation of IRS-1 was performed as described in (A), with the exception that immunoprecipitations were performed using an anti-IRS-1-specific antiserum. The upper panel shows results of a typical experiment; the lower panel, the quantitation of results obtained for at least four animals under each condition, expressed as in (A).
(C) Insulin-stimulated tyrosine phosphorylation of IRS-2 was assessed in a manner similar to that described for IRS-1 in part (B), except that immunoprecipitations were performed with an anti-IRS-2-specific antiserum. The top panel shows a representative experiment; the bottom panel, the quantitation of 4-6 animals for each experimental condition.
(D) Insulin-stimulated association of p85, the regulatory subunit of PI 3-kinase, with IRS-1 was assayed by performing immunoprecipitations using an anti-IRS-1-specific antiserum, followed by Western blot analysis using an anti-p85-specific antiserum. The upper panel shows results of a typical experiment; the lower panel, quantitation of four independent determinations for each experimental condition. Data are expressed as percentage of the signal intensity obtained for the sample of the insulin-stimulated wild-type animal.
(E) Insulin-stimulated association of p85 with IRS-2 was assayed as described in part (D), with the exception that IRS-2-specific antisera were used for the immunoprecipitations. The upper panel shows the result of an exemplary experiment; the lower panel, the quantitation of five experiments presented as percentage of the intensity found in the insulin-stimulated wild-type animals. glucose concentrations of IRS-1 (ϩ/Ϫ), IR (ϩ/Ϫ), and dramatically. Thus, by this age, the IR (ϩ/Ϫ) mice exhibited 5-fold elevated plasma insulin concentrations, and IR/IRS-1 (ϩ/Ϫ) mice when examined shortly after birth (data not shown) or at the age of 2 months ( Figure 5A ). those in IR/IRS-1 (ϩ/Ϫ) mice were 13-fold elevated (Figure 5D ). This insulin resistance was confirmed in the At 2 months, however, insulin levels already suggested an incremental effect of the two mutations on insulin insulin tolerance tests. Blood glucose levels in wildtype mice fell by 45% over a 1 hr period following an resistance. Thus, insulin levels in the fed state were increased ‫%03ف‬ in IRS-1 (ϩ/Ϫ) mice (n.s.), 1.9-fold in intraperitoneal injection of insulin, but dropped only by 30%-35% in IRS-1 (ϩ/Ϫ) and IR (ϩ/Ϫ) heterozygotes IR (ϩ/Ϫ) mice (p Ͻ 0.05), and 2.6-fold (p Ͻ 0.05) in the double heterozygotes as compared to wild-type animals ( Figure 5E ). Even more dramatic results were obtained when IR/IRS-1 (ϩ/Ϫ) mice were examined. In these mice, ( Figure 5B ). Intraperitoneal insulin tolerance tests performed with 0.75 U/kg body weight, however, were not blood glucose concentrations dropped by ‫%02ف‬ at 30 min after insulin injection and began to rise again by 1 sensitive enough to detect a significant difference in the blood glucose-lowering effect of exogenously adminishr. Thus, the double heterozygous mice were the only group examined reaching statistical significance, as tered insulin at this age ( Figure 5C ).
When the animals were reexamined between the ages compared to wild-type animals with regard to insulin resistance in intraperitoneal tolerance testing (p Ͻ 0.01) of 4 and 6 months, insulin resistance had increased ( Figure 5E ). These data, together with the markedly elecompared to wild-type animals ( Figure 6B , left panel). The ␤ cell mass increased in parallel to the insulin resisvated plasma insulin concentrations in IR/IRS-1 (ϩ/Ϫ) mice, indicate that two mild defects in the insulin signaltance, but in no group did non-␤ cell mass differ from wild-type mice ( Figure 6B , right panel). Thus, there was ing cascade can act synergistically in producing insulin resistance.
a selective increase in ␤ cells in these insulin resistant mice. The enormous increase in ␤ cells in the double Also, over time, the insulin resistance produced by two 50% defects in insulin signaling was sufficient to heterozygote animals resulted in distorted islet morphology. In the wild-type mice, the non-␤ cells (20%-30% cause an increased rate of diabetes, even in the absence of obesity or overt ␤ cell injury. Analysis of blood glucose of the islet) form a discontinuous mantle 1-2 cells thick around a core of ␤ cells (70%-80% of the islet) (Figure concentrations revealed a tight range in which random fed glucose concentrations were regulated in wild-type 6C). However, in the IR/IRS-1 (ϩ/Ϫ) mice, the non-␤ cells, which represent 8% of the islet, are scattered animals ( Figure 5F ). Blood glucose concentrations in IRS-1 (ϩ/Ϫ) were indistinguishable from those found in irregularly throughout the islet periphery ( Figure 6C ). According to the multistep model of NIDDM, the ocwild-type mice ( Figure 5F ). These data are consistent with our previous findings that no wild-type or IRS-1 currence of diabetes can result from a relative or absolute failure of pancreatic ␤ cells to secrete enough insulin (ϩ/Ϫ) animal monitored in our laboratory over the past three years has developed diabetes. Moderate insulin to overcome insulin resistance and maintain euglycemia. When we compared additional IR/IRS-1 (ϩ/Ϫ) resistance in the IR (ϩ/Ϫ) mice resulted in the occurrence of hyperglycemia in some of these mice. While mice of known phenotype (diabetic or nondiabetic), the most extensive ␤ cell hyperplasia was found in the diamost of them exhibited blood glucose concentrations within the range of control animals, some mice exhibited betic mice. Indeed, the diabetic IR/IRS-1 (ϩ/Ϫ) animals had a mean random fed blood glucose value of 300 mg/ mild hyperglycemia in the fed state ( Figure 5F ). Out of 40 animals characterized during the course of these dl ( Figure 7A ), a 15-fold increase in ␤ cell mass ( Figure  7B ), and 21-fold elevated plasma insulin levels (Figure studies, only four (10%) developed severe hyperglycemia of more than 250 mg/dl on multiple individual deter-7C) as compared to wild-type animals. In contrast, the euglycemic double heterozygote mice had mean blood minations. This rate of diabetes is consistent with an incidence rate of diabetes of ‫%01ف‬ when 150 IR (ϩ/Ϫ) glucose values of 120 mg/dl ( Figure 7A ), a 3-fold increase in ␤ cell mass ( Figure 7B ), and a 4-fold elevation mice were studied in an independent animal facility (data not shown). In contrast, IR/IRS-1 (ϩ/Ϫ) mice showed a in plasma insulin levels ( Figure 7C ). Even so, the occurrence of diabetes indicates that the ␤ cells were unable markedly increased incidence of disease. Thus, only ‫%04ف‬ were able to maintain glucose concentrations in to completely compensate for the insulin resistance caused by heterozygosity of IR and IRS-1 null alleles. a normal range, several exhibited moderate hyperglycemia, and 24 out of 61 IR/IRS-1 (ϩ/Ϫ) mice (39.3%) beThus, there is a state of "relative" insulin deficiency in which these double heterozygote animals were not able came overtly diabetic by the age of 6 months with blood glucose concentrations of more than 250 mg/dl (Figure to maintain euglycemia. Whether absolute insulin deficiency would develop over time remains to be deter-5F). Although IR/IRS-1 (ϩ/Ϫ) mice of both genders were highly insulin resistant and developed diabetes, the male mined. mice were more strongly affected than their female litter mates (75% of the diabetic animals versus 25%). In Discussion summary, although a 50% deficiency in IRS-1 or in insulin receptor alone causes diabetes in only a few mice, Insulin and IGF-1 mediate a variety of essential signals these two defects act synergistically to cause a signififor vertebrate growth and metabolism. The most promicantly increased incidence of disease. nent function of insulin is the maintenance of euglycemia, which is achieved by stimulation of glucose disposal in muscle and fat and inhibition of hepatic glucose Increasing Degrees of Insulin Resistance Cause Pancreatic ␤ Cell Hyperplasia production. Longitudinal studies have shown that the first step in the pathogenesis of NIDDM is resistance and Hyperinsulinemia In the multistep model for the pathogenesis of NIDDM, to insulin-stimulated glucose uptake in skeletal muscle (Martin et al., 1992; Lillioja et al., 1993) . Insulin resistance insulin resistance precedes the appearance of hyperglycemia and is accompanied by increased pancreatic incan initially be overcome by elevated plasma insulin concentrations, but after a period of time this mechasulin production. This situation is reflected in the progressively elevated insulin levels found in IR/IRS-1 (ϩ/Ϫ) nism is no longer able to compensate sufficiently and hyperglycemia occurs. The underlying molecular and mice. To assess the impact of different degrees of insulin resistance on pancreatic compensation in these differgenetic mechanisms for insulin resistance and the factors responsible for progression to frank diabetes are ent mutant mice, we examined the pancreas histologically after immunostaining for insulin ( Figure 6A ) and still unknown. The animal model presented here indicates that the combination of minor defects in the insulin determined pancreatic ␤ cell and non-␤ cell masses by point-counting morphometry. In 6-month-old male mice, signaling cascade can act synergistically to cause insulin resistance and NIDDM. even though there were no differences in body weight or pancreatic weight, the ␤ cell mass was increased 2-The double heterozygote IR/IRS-1 (ϩ/Ϫ) mice model fulfills three criteria that are not present in other rodent to 3-fold in IRS-1 (ϩ/Ϫ) and IR (ϩ/Ϫ) mice and 2-to 30-fold (mean 10-fold) in the IR/IRS-1 (ϩ/Ϫ) mice as models but closely mimic human NIDDM. First, this model is polygenic in nature and is the result of rather for the IRS-1 deficiency, IR/IRS-1 (ϩ/Ϫ) mice exhibit a disproportionately severe insulin resistance in skeletal modest genetic defects. NIDDM clearly has a genetic component, and several studies suggest a polygenic muscle as compared to liver, mimicking the defect seen in most individuals prior to development of NIDDM. nature of the disease. Metabolic defects in NIDDM, whether genetic or acquired, are usually relatively mild;
Third, the onset of diabetes is age-dependent. This also reflects the typical course of human NIDDM, which is these include the defects in signaling that occur with mutant IRS-1 molecules or the decrease in signaling that rare before the age of 20 and gradually increases with aging. In humans, this period can be accelerated by results from insulin receptor down-regulation (Prince et al., 1981; Olefsky et al., 1982; Caro et al., 1987 ; Almind obesity and/or sedentary life style, factors that might also be superimposed in the NIDDM mouse. Therefore, et al., 1996) . Second, the first detectable defect in our model is resistance to the blood glucose-lowering effect the animals created reflect thus far the only rodent model that represents the clinical picture of human of insulin, and this can occur even in the absence of obesity. Since skeletal muscle is responsible for 80% of NIDDM. These characteristics of the NIDDM mouse provide insulin-stimulated glucose transport, and since skeletal muscle has a relatively low level of IRS-2 to compensate clues that may redirect research to find the underlying defects in NIDDM humans. Research thus far has foof NIDDM. However, it is particularly difficult to test this hypothesis in human populations, owing to the complexcused on the identification of major gene effects caused by mutations of the insulin receptor signaling network.
ity of the gene pool and the possibility that even within relatively homogenous populations, different genes may The animal model presented here suggests that minor defects acting in concert with each other can cause interact in the pathogenesis of different individuals to produce the insulin resistance and insulin secretory designificant insulin resistance and overt NIDDM. Reduced expression of the insulin receptor comparable to what fects.
The NIDDM mouse provides a practical demonstrais seen in these mice ‫)%05ف(‬ is found in tissues of obese insulin-resistant people (Bar et al., 1976) , diabetic tion of epistatic interactions among different genes in the same pathway. The somewhat bimodal distribution patients (Kolterman et al., 1981; Prince et al., 1981; Olefsky et al., 1982; , and most of the of glucose concentrations into diabetic and nondiabetic animals suggests that only one or two additional genes obesity-linked rodent models of NIDDM (Kahn et al., 1973) . Likewise, previous studies have shown a reducmay be required to give rise to a "clinically apparent" phenotype. The phenotypic variation within each subtion of IRS-1 expression in both NIDDM and obesity in humans and rodents (Saad et al., 1993; Goodyear et al., population may in part be explained by the mixed genetic background (C57Bl/6J and 129 sv) used to derive 1995), and this is of similar magnitude to that seen in heterozygous IRS-1 deficiency. Furthermore, as noted the IR/IRS-1 (ϩ/Ϫ) mice. It is likely that additional diabetes susceptibility alleles are present in these two strains. above, IRS-1 sequence variations have been found with an increased frequency in many diabetic populations Indeed, our use of mixed strains of mice was designed to mimic as closely as possible the genetics of diabetes (Almind et al., 1993; Laakso et al., 1994; Clausen et al., 1995) . When expressed in cultured cells, the most in an outbred population. The identification of additional susceptibility loci using quantitative trait linkage analycommon of these mutant IRS-1s exhibits an ‫%03ف‬ reduction of insulin-stimulated PI 3-kinase activation (Alsis on backcrosses of the NIDDM mouse should provide information on the number and location of such loci mind et al., 1996) . While the relatively modest magnitude of this defect might be considered of questionable bioand suggest important syntenic regions for investigators pursuing genome scans of NIDDM in human populations logical significance, it is comparable to the defect seen in IRS-1 (ϩ/Ϫ) mice. Indeed, we have shown here that (Vaxillaire et al., 1995) . Another area of extensive research is the search for this defect can act in concert with a second mild defect in the insulin signaling cascade to cause progression pancreatic ␤ cell growth and survival factors. We have demonstrated that IR/IRS-1 (ϩ/Ϫ) mice exhibit extentoward NIDDM. It is likely that the combination of various other defects in the insulin signaling cascade can cause sive ␤ cell hyperplasia that allows for partial or complete compensation of the severe insulin resistance by elea similar phenotype.
Another important implication from this mouse model vated plasma insulin levels. Since even the euglycemic, nondiabetic animals exhibit up to 5-fold elevated ␤ cell for the genetics of NIDDM is the ability to use these mice of a well-defined phenotype as an indicator for mass, this model may provide important clues for islet growth and survival. As has been shown previously, ␤ identification of other genetic factors causing insulin resistance. Since environmental factors within our anicell mass is dynamic and can compensate for increased demand (Bonner-Weir, 1994) . In double heterozygous mal colony are similar for all the mice, it seems likely that genetic factors other than the knockout mutation animals at 1 month of age, little hyperinsulinemia is detectable, and there is no ␤ cell hyperplasia (data not influence the phenotype. The genetics of NIDDM in humans also follows a complex pattern of inheritance, indishown). Therefore, there must exist a ␤ cell growth factor that is able to stimulate the massive ␤ cell proliferation cating that it is unlikely that NIDDM is caused by a single mutation in a major gene. While different explanations in the young animals. Although glucose has been shown to stimulate ␤ cell growth (Bonner-Weir et al., 1989) , have been set forth to account for this complex pattern of inheritance, the notion that NIDDM may develop as this factor is probably something in addition to glucose, since we can already detect a significant degree of islet a result of different mutations at different loci acting simultaneously and in a synergistic manner (epistasis) cell hyperplasia in normoglycemic IR/IRS-1 (ϩ/Ϫ) mice.
The mouse model presented here may help to identify provides a unifying hypothesis for the complex genetics mouse strains, such as the C57Bl/ks, that carry genes ␤ cell mass was measured by point-counting morphometry as preencoding a susceptibility for ␤ cell failure. Breeding the viously described (Bonner-Weir et al., 1989) .
NIDDM mouse onto these background strains will greatly facilitate the identification of such genes, since
Statistical Analyses
it is clear that the IR/IRS-1 (ϩ/Ϫ) rely on massive ␤ cell Each variable was analyzed using the unpaired Student's t test. For hyperplasia to maintain euglycemia for a period of time.
all analyses, a p value of less than 0.05 was considered significant. Results are given as means ϩ/Ϫ SEM.
Thus, there should be an increased rate or earlier onset of NIDDM when the IR/IRS-1 (ϩ/Ϫ) genotype is bred proteins were performed on muscle and liver homogenates as pre-
In conclusion, we have created a novel polygenic viously described (Araki et al., 1994) . Results are expressed as permodel for the most common endocrine disease, NIDDM.
centage of signal intensity seen in samples from insulin-stimulated In many ways, NIDDM is similar to other common diswild-type animals.
eases such as atherosclerosis, hyperlipidemia, and obesity, in which longitudinal studies suggest complex pat-
